Frontotemporal Dementia, Where Do We Stand? A Narrative Review

被引:35
|
作者
Antonioni, Annibale [1 ,2 ]
Raho, Emanuela Maria [1 ]
Lopriore, Piervito [3 ]
Pace, Antonia Pia [4 ]
Latino, Raffaela Rita [5 ]
Assogna, Martina [6 ,7 ]
Mancuso, Michelangelo [3 ]
Gragnaniello, Daniela [8 ]
Granieri, Enrico [1 ]
Pugliatti, Maura [1 ]
Di Lorenzo, Francesco [7 ]
Koch, Giacomo [7 ,9 ,10 ]
机构
[1] Univ Ferrara, Neurosci & Rehabil Dept, Unit Clin Neurol, I-44121 Ferrara, Italy
[2] Univ Ferrara, Doctoral Program Translat Neurosci & Neurotechnol, I-44121 Ferrara, Italy
[3] Univ Pisa, Neurol Inst, Dept Clin & Expt Med, I-56126 Pisa, Italy
[4] Univ Udine, Univ Hosp S Maria Misericordia, Azienda Sanit Universitaria Friuli Cent, Inst Radiol,Dept Med, I-33100 Udine, Italy
[5] Fdn Ist Ricovero & Cura Carattere Sci Casa Solliev, Emergency Dept, Complex Struct Neurol, I-71013 San Giovanni Rotondo, Italy
[6] Univ Roma Tor Vergata, Ctr Demenze, Policlin Tor Vergata, I-00133 Rome, Italy
[7] Ist Ricovero & Cura Carattere Sci Santa Lucia, Non Invas Brain Stimulat Unit, I-00179 Rome, Italy
[8] Ferrara Univ Hosp, Neurosci & Rehabil Dept, Nuerol Unit, I-44124 Ferrara, Italy
[9] Ist Italiano Tecnol, IitUnife Ctr Translat Neurophysiol, I-44121 Ferrara, Italy
[10] Univ Ferrara, Neurosci & Rehabil Dept, Sect Human Physiol, I-44121 Ferrara, Italy
关键词
frontotemporal dementia (FTD); primary progressive aphasias; behavioural variant; neurodegenerative dementias; biomarkers; non-Alzheimer's disease dementias; tau; C9orf72; AMYOTROPHIC-LATERAL-SCLEROSIS; PRIMARY PROGRESSIVE APHASIA; TRANSCRANIAL MAGNETIC STIMULATION; HEXANUCLEOTIDE REPEAT EXPANSION; CEREBROSPINAL-FLUID LEVELS; NEUROFILAMENT LIGHT-CHAIN; FRONTAL-LOBE DEGENERATION; RIGHT TEMPORAL VARIANT; BEHAVIORAL-VARIANT; ALZHEIMERS-DISEASE;
D O I
10.3390/ijms241411732
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Frontotemporal dementia (FTD) is a neurodegenerative disease of growing interest, since it accounts for up to 10% of middle-age-onset dementias and entails a social, economic, and emotional burden for the patients and caregivers. It is characterised by a (at least initially) selective degeneration of the frontal and/or temporal lobe, generally leading to behavioural alterations, speech disorders, and psychiatric symptoms. Despite the recent advances, given its extreme heterogeneity, an overview that can bring together all the data currently available is still lacking. Here, we aim to provide a state of the art on the pathogenesis of this disease, starting with established findings and integrating them with more recent ones. In particular, advances in the genetics field will be examined, assessing them in relation to both the clinical manifestations and histopathological findings, as well as considering the link with other diseases, such as amyotrophic lateral sclerosis (ALS). Furthermore, the current diagnostic criteria will be explored, including neuroimaging methods, nuclear medicine investigations, and biomarkers on biological fluids. Of note, the promising information provided by neurophysiological investigations, i.e., electroencephalography and non-invasive brain stimulation techniques, concerning the alterations in brain networks and neurotransmitter systems will be reviewed. Finally, current and experimental therapies will be considered.
引用
收藏
页数:34
相关论文
共 50 条
  • [21] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [22] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [23] Where do we stand in the OECD?
    Buske, L
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1997, 156 (03) : 464 - 464
  • [24] Where do we stand with hepatoblastoma?
    Schnater, JM
    Köhler, SE
    Lamers, WH
    von Schweinitz, D
    Aronson, DC
    CANCER, 2003, 98 (04) : 668 - 678
  • [25] Inflation: Where do we stand?
    Martin, J
    INTERNATIONAL JOURNAL OF MODERN PHYSICS A, 2005, 20 (19): : 4676 - 4682
  • [26] GFIS - Where do we stand?
    Anon
    IUFRO News, 2002, 31 (02):
  • [27] The GSEs: Where do we stand?
    Poole, William
    FEDERAL RESERVE BANK OF ST LOUIS REVIEW, 2007, 89 (03): : 143 - 151
  • [28] VITILIGO - WHERE DO WE STAND
    ORTONNE, JP
    BOSE, SK
    PIGMENT CELL RESEARCH, 1993, 6 (02): : 61 - 72
  • [29] Where do we stand on econophysics?
    Carbone, A.
    Kaniadakis, G.
    Scarfone, A. M.
    PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS, 2007, 382 (01) : XI - XIV
  • [30] WHERE DO WE STAND WITH PPIS
    WELSH, JS
    AMERICAN PHARMACY, 1979, 19 (12): : 12 - 14